GP Pharm

Name

GP Pharm

Legal name

GP PHARM, S.A.

Website

https://gp-pharm.com

Company type

Private

Founded year

2000

Operating status

Operating

Headcount range

101–250 employees

Short description

GP Pharm is a private Spanish biopharmaceutical company that develops, manufactures, and commercializes complex injectable pharmaceuticals — proprietary microsphere, liposome, and lipid nanoparticle formulations — in Oncology, Urology, and Women's Health, serving global markets through its own products, CDMO services, and out-licensing partnerships.

Ownership category

akta.pro rank

Product category

Injectable Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Specialty Injectable & Infusion Therapies (Cross-therapeutic) (HLAIACAO)

akta.pro secondary industries

CMC & Pharmaceutical Development (Formulation/Process/Analytical Development) (HLAIALAD), GMP Scale-Up, Tech Transfer & Process Validation (PPQ) (HLAGAHAL)

Keywords

• Injectable pharmaceuticals
• Extended-release drug delivery
• Microencapsulation technology
• CDMO services
• Biopharmaceutical manufacturing

Headquarters

HQ city

Hospitalet De Llobregat

HQ country

Spain

HQ region

Europe

Offices3 records

Markets served

GTM type

B2B and B2C

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales, Supply Chain

Revenue model

1. Product Commercialization (B2C - Spain): GP Pharm commercializes its own injectable pharmaceutical products in Spain through its own commercial network, combining proprietary products with licensed-in products from other companies to offer therapies in Urology, Oncology, Women's Health, and hospital products. This is the company's primary domestic revenue driver.
2. Out-Licensing and Partnering (B2B - International): GP Pharm enters into out-licensing and partnering agreements with international pharmaceutical companies to commercialize its proprietary products in specific territories. These agreements generate revenue through upfront payments, milestone payments, and ongoing royalties. Current agreements cover much of Europe, the United States, Canada, Latin America, MENA, Asia, and Oceania.
3. CDMO Services (Contract Development & Manufacturing): GP Pharm offers its specialized development and manufacturing capabilities to third-party pharmaceutical companies through its CDMO division. Services include manufacture of investigational, preclinical, validation, and commercial injectable products and lyophilized pharmaceuticals. The company is authorized for manufacture under Annex 13 of cGMP for clinical batches.
4. In-Licensing / Product Licensing: GP Pharm identifies and licenses products from known and reputable manufacturers to expand its domestic product portfolio in Spain, complementing its own developed products with additional therapeutic offerings.

Go-to-market motion3 records

Distribution channels4 records

Marketing channels10 records

Core offering

GP Pharm develops, manufactures, and commercializes injectable pharmaceutical products based on proprietary microencapsulation drug delivery technologies including microspheres, liposomes, and lipid nanoparticles. Its core therapeutic focus areas are Oncology, Urology, and Women's Health. The company operates across four integrated business areas: proprietary R&D+i product development, CDMO contract manufacturing services for third-party pharmaceutical companies, B2B international out-licensing and partnering, and B2C direct commercialization in Spain.

Product overview

GP Pharm is a private pharmaceutical company founded in 2000 in Barcelona, specializing in injectable products with focus on extended-release drug delivery systems. The company's product portfolio comprises two categories: (1) Own/international products developed using proprietary technology including Lutrate Depot (leuprolide microspheres for oncology and women's health), Duratil (teriparatide for osteoporosis), Astarté (ganirelix for assisted reproduction), Nictur (oral desmopressin), Carbetocin, Icatibant, Octreotide, and Somatostatin; (2) Licensed national products for the Spanish market including Galdar, Gepex, Amenur (oncology), Duplotrip, Tasoltrip, Zuantrip, Zuandol, Acore, Wibical (urology). The business model integrates four areas: R&D+i focusing on microencapsulation technologies, CDMO contract manufacturing services, B2B partnering/out-licensing, and B2C commercialization in Spain.

Differentiator

Problem solved

Functional benefit

Products and services

• Lutrate Depot - 1 Month Leuprolide extended-release injectable suspension (3.75 mg) for palliative treatment of advanced hormone-dependent prostate cancer, uterine fibroids, endometriosis, and breast cancer. Based on patented GP Pharm technology.
• Lutrate Depot - 3 Month Leuprolide extended-release injectable suspension (22.5 mg) for palliative treatment of advanced hormone-dependent prostate cancer. Quarterly formulation developed based on patented technology owned by GP Pharm.
• Duratil Teriparatide solution for injection (250 µg/ml) in pre-filled pen for treatment of osteoporosis in postmenopausal women and men.
• Astarté Ganirelix solution for injection (0.25 mg/0.5 ml) in pre-filled syringe for prevention of premature LH peaks in controlled ovarian hyperstimulation for assisted reproductive techniques.
• Nictur Desmopressin oral solution (360 µg/ml), the first oral desmopressin solution on the market, for treatment of central diabetes insipidus and primary nocturnal enuresis.
• Carbetocin GP-Pharm Carbetocin solution for injection (100 µg) in pre-filled syringe for prevention of postpartum haemorrhage.
• Icatibant GP-Pharm Icatibant injectable solution (30 mg) in pre-filled syringe for symptomatic treatment of acute attacks of hereditary angioedema.
• Octreotide GP-Pharm Octreotide acetate injectable and infusion solution (50-500 µg/ml) for treatment of acromegaly, GEP endocrine tumors, and prevention of complications after pancreatic surgery.
• Somatostatin GP-Pharm Somatostatin lyophilized powder (3 mg) for treatment of gastrointestinal bleeding due to esophageal varices rupture.
• CDMO Services Contract Development and Manufacturing Organisation services offering research, development, and production of injectable pharmaceuticals including cytotoxic ingredients, HPAPIs (peptides, oligonucleotides, hormones), and extended-release drug systems (microspheres, liposomes, lipid nanoparticles, micellar solutions). Authorized for manufacture under Annex 13 of cGMP for clinical batches.

Quantifiable outcome

• GP Pharm products are available across Europe, USA, Canada, Latin America, MENA, Asia, and Oceania through partnering agreements.
• +1 more outcomes

Named customers3 records

Segments5 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Four partnerships are on record, tiered core and minor.

• TEVA (formerly Cephalon)coreOEM/ Whitelabel/ Licensing Partner · 1 January 2007In 2007, Cephalon (now TEVA) appointed GP Pharm as the exclusive manufacturer of Myocet® (Liposomal Doxorubicin), a liposomal doxorubicin product. This represents a long-standing manufacturing partnership where GP Pharm serves as the exclusive CDMO supplier for this established oncology product.
• Smart Vitamins SLminorStrategic or Co-development PartnerSmart Vitamins SL is a spin-off from the University of Santiago de Compostela developing SV B-I therapy for flu prevention. GP Pharm has collaborated with this biotech startup, with GP Pharm's involvement reported in 2025 news coverage of the company.
• International Pharmaceutical CompaniescoreChannel Partner/ Reseller/ DistributorGP Pharm has established strategic alliances with international pharmaceutical companies to commercialize its products in specific territories. Current partnering agreements cover much of Europe, the United States, Canada, Latin America, MENA, Asia, and Oceania, enabling global patient access to GP Pharm's injectable therapies.
• Volsunga GroupcoreOthersGP Pharm S.A. is a company of the Volsunga Group, headquartered in Sant Quintí de Mediona, Barcelona. The Volsunga Group encompasses multiple companies including BCN Corp, and GP Pharm operates as part of this corporate group.

Scale indicators4 records

Recent moves8 records

Expansion highlights4 records

Broad incumbents

• Patheon (Thermo Fisher Scientific): Global large-scale CDMO within Thermo Fisher offering sterile injectable development and commercial manufacturing. Competes with GP Pharm for CDMO contracts but at significantly greater scale and broader service portfolio.
• Teva Pharmaceutical Industries: Global generic and specialty pharma giant that is both a CDMO customer (Myocet exclusive manufacturing by GP Pharm) and a competitor in leuprolide and injectable generics. Relevant as both a partner and competitive threat.

Direct peers

• Hovione: Portugal-headquartered CDMO with recognized expertise in particle engineering, including microspheres and lipid nanoparticles for injectable drug delivery. Highly comparable technology overlap with GP Pharm's microencapsulation platform.
• Recipharm: European CDMO offering sterile injectable manufacturing and development services. Competes with GP Pharm for injectable CDMO contracts, with overlapping capabilities in aseptic fill-finish and complex formulations.
• Tolmar Pharmaceuticals: Specialty pharma focused on long-acting injectable technologies with Eligard (leuprolide) as a flagship product directly competing with GP Pharm's Lutrate Depot. Comparable in proprietary long-acting injectable platform and oncology/urology therapeutic focus.
• Evonik Health Care: Specializes in CDMO services for complex parenteral drug delivery, including lipid nanoparticles, polymeric microspheres, and HPAPI handling. Direct technology overlap with GP Pharm's lipid nanoparticle and microsphere capabilities.
• Laboratorios Farmacéuticos ROVI: Spanish specialty pharmaceutical company specializing in injectables and drug delivery systems, with proprietary technology platforms (e.g., ISM) for extended-release injectables and a CDMO division. Highly comparable to GP Pharm in geographic origin, therapeutic focus, and vertically integrated model.
• Siegfried Holding: Swiss-listed CDMO offering sterile injectable fill-finish and API manufacturing. Competes with GP Pharm in the injectable CDMO market and shares European geographic anchoring.
• Vetter Pharma: Germany-based specialist CDMO focused on complex injectable fill-finish (vials, pre-filled syringes, cartridges). Comparable as a high-end injectable CDMO serving large pharma with specialized capabilities, similar to GP Pharm's CDMO division.

Emerging players

• Ardena: European CDMO with growing capabilities in sterile injectables and complex formulations, including nanomedicines. Smaller scale than top-tier CDMOs but overlapping with GP Pharm's complex injectable service offering.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInes.linkedin.com/company/lab.-gp-pharm

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about GP Pharm